Friday, July 10, 2026

pharma · Acute myeloid leukemia · Juvenile idiopathic arthritis

Istituto Gentili Italia

Istituto Gentili Italia clinical programs — 50 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Via San Giuseppe Cottolengo, 15, Milano, Lombardia 20143, IT HQ
1917 Founded
121 Employees
EMA registrant Type
Company details
Status
Public
HQ
Via San Giuseppe Cottolengo, 15, Milano, Lombardia 20143, IT
Founded
1917
Employees
121
Programs
50
Drugs
114
Patents
0
Intelligence · Clinical Programs

Istituto Gentili Italia projects

50 ClinicalTrials.gov programs sponsored by Istituto Gentili Italia.

Istituto Gentili Italia has 50 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

Clinical programs

Page 2 of 2
  1. Re-JIA

    Istituto Gentili S.r.l.

    Juvenile idiopathic arthritis

    approved small molecule active

    1 trial
  2. The MIRAGE trial

    Istituto Gentili S.r.l.

    cesarean section

    approved small molecule active

    1 trial

Frequently asked questions

How many clinical projects does Istituto Gentili Italia have?

50 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.